
Lei Yao
Examiner (ID: 4598, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1313 |
| Issued Applications | 647 |
| Pending Applications | 150 |
| Abandoned Applications | 544 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20231358
[patent_doc_number] => 20250288677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-18
[patent_title] => MULTIPHASIC LOCALIZED IN VIVO MOLECULAR DELIVERY
[patent_app_type] => utility
[patent_app_number] => 19/080387
[patent_app_country] => US
[patent_app_date] => 2025-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19080387
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/080387 | MULTIPHASIC LOCALIZED IN VIVO MOLECULAR DELIVERY | Mar 13, 2025 | Pending |
Array
(
[id] => 20231358
[patent_doc_number] => 20250288677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-18
[patent_title] => MULTIPHASIC LOCALIZED IN VIVO MOLECULAR DELIVERY
[patent_app_type] => utility
[patent_app_number] => 19/080387
[patent_app_country] => US
[patent_app_date] => 2025-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19080387
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/080387 | MULTIPHASIC LOCALIZED IN VIVO MOLECULAR DELIVERY | Mar 13, 2025 | Pending |
Array
(
[id] => 20302675
[patent_doc_number] => 12448654
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-21
[patent_title] => Compositions and methods for detecting pancreatic cancer
[patent_app_type] => utility
[patent_app_number] => 18/749771
[patent_app_country] => US
[patent_app_date] => 2024-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 45
[patent_no_of_words] => 11463
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18749771
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/749771 | Compositions and methods for detecting pancreatic cancer | Jun 20, 2024 | Issued |
Array
(
[id] => 19550951
[patent_doc_number] => 12134647
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => Binding molecules
[patent_app_type] => utility
[patent_app_number] => 18/405910
[patent_app_country] => US
[patent_app_date] => 2024-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 8
[patent_no_of_words] => 32814
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18405910
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/405910 | Binding molecules | Jan 4, 2024 | Issued |
Array
(
[id] => 19300062
[patent_doc_number] => 20240228631
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-07-11
[patent_title] => Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/501589
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 371
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501589
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501589 | Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof | Nov 2, 2023 | Abandoned |
Array
(
[id] => 19300062
[patent_doc_number] => 20240228631
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-07-11
[patent_title] => Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/501589
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 371
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501589
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501589 | Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof | Nov 1, 2023 | Abandoned |
Array
(
[id] => 19156179
[patent_doc_number] => 20240148886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => INTRACELLULAR DELIVERY COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/381344
[patent_app_country] => US
[patent_app_date] => 2023-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33901
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18381344
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/381344 | INTRACELLULAR DELIVERY COMPOSITIONS | Oct 17, 2023 | Pending |
Array
(
[id] => 18612380
[patent_doc_number] => 20230279112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT BIND TO BTN1A1 OR BTN1A1-LIGANDS
[patent_app_type] => utility
[patent_app_number] => 18/066879
[patent_app_country] => US
[patent_app_date] => 2022-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61370
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18066879
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/066879 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT BIND TO BTN1A1 OR BTN1A1-LIGANDS | Dec 14, 2022 | Pending |
Array
(
[id] => 18725882
[patent_doc_number] => 20230340116
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 18/063367
[patent_app_country] => US
[patent_app_date] => 2022-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063367
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/063367 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS | Dec 7, 2022 | Pending |
Array
(
[id] => 18392679
[patent_doc_number] => 20230160899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => USE OF TENASCIN-C AS AN EXTRACELLULAR MARKER OF TUMOR-DERIVED MICROPARTICLES
[patent_app_type] => utility
[patent_app_number] => 18/060455
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060455
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060455 | Use of Tenascin-C as an extracellular marker of tumor-derived microparticles | Nov 29, 2022 | Issued |
Array
(
[id] => 18612379
[patent_doc_number] => 20230279111
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => MODIFIED J-CHAIN
[patent_app_type] => utility
[patent_app_number] => 18/052388
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17019
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052388
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052388 | MODIFIED J-CHAIN | Nov 2, 2022 | Pending |
Array
(
[id] => 18612379
[patent_doc_number] => 20230279111
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => MODIFIED J-CHAIN
[patent_app_type] => utility
[patent_app_number] => 18/052388
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17019
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052388
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052388 | MODIFIED J-CHAIN | Nov 2, 2022 | Pending |
Array
(
[id] => 18738030
[patent_doc_number] => 20230346938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/049151
[patent_app_country] => US
[patent_app_date] => 2022-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049151
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/049151 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF | Oct 23, 2022 | Pending |
Array
(
[id] => 18437482
[patent_doc_number] => 20230184777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/046606
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16732
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046606
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046606 | DIAGNOSIS AND TREATMENT OF CANCER | Oct 13, 2022 | Pending |
Array
(
[id] => 18676808
[patent_doc_number] => 20230314441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/046619
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16724
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046619
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046619 | DIAGNOSIS AND TREATMENT OF CANCER | Oct 13, 2022 | Pending |
Array
(
[id] => 18676808
[patent_doc_number] => 20230314441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/046619
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16724
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046619
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046619 | DIAGNOSIS AND TREATMENT OF CANCER | Oct 13, 2022 | Pending |
Array
(
[id] => 18451584
[patent_doc_number] => 20230192862
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ANTIBODIES BINDING 4-1BB AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/045133
[patent_app_country] => US
[patent_app_date] => 2022-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045133
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045133 | ANTIBODIES BINDING 4-1BB AND USES THEREOF | Oct 6, 2022 | Pending |
Array
(
[id] => 18376009
[patent_doc_number] => 20230151091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => THERAPEUTIC MUSK ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/937630
[patent_app_country] => US
[patent_app_date] => 2022-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937630
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/937630 | THERAPEUTIC MUSK ANTIBODIES | Oct 2, 2022 | Pending |
Array
(
[id] => 18451564
[patent_doc_number] => 20230192842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/950667
[patent_app_country] => US
[patent_app_date] => 2022-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17950667
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/950667 | CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER | Sep 21, 2022 | Pending |
Array
(
[id] => 18725907
[patent_doc_number] => 20230340148
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => METHOD FOR TREATING A GD2 POSITIVE CANCER
[patent_app_type] => utility
[patent_app_number] => 17/933295
[patent_app_country] => US
[patent_app_date] => 2022-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18264
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933295 | METHOD FOR TREATING A GD2 POSITIVE CANCER | Sep 18, 2022 | Pending |